Definium Therapeutics, Inc. (DFTX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreNews headlines
Powered by Yahoo ScoutDefinium Therapeutics is approaching its November 9, 2026 third-quarter results webcastafter reporting positive Phase III data for DT120 in anxiety and depression. The company plans an FDA pre-NDA meeting in late 2026 and expects a New Drug Application filing in the first half of 2027. DFTX is down 4.29% in the current regular session on November 1, 2026, while recent coverage highlights valuation, clinical execution, cash resources, and regulatory progress.
